SCHEMBL6200319

SCHEMBL6200319

Fc1ccc(-c2c(-c3ccc(Cl)nc3)oc3ncnc(Cl)c23)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
HPGD P15428 3/20 0.41
KDM4E B2RXH2 2/20 0.41
UBE2N P61088 2/20 0.41
TSHR P16473 2/20 0.41
HSD17B10 Q99714 2/20 0.41
MEN1 O00255 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TNK2 Q07912 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 1/20 0.39
TEK Q02763 4/20 0.39
KDR P35968 2/20 0.39
GSK3B P49841 3/20 0.38
RPS6KB1 P23443 3/20 0.38
AURKA O14965 2/20 0.36
MERTK Q12866 1/20 0.35
MAPK14 Q16539 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6202574 0.88 TNK2 (0.53) ALDH1A1HPGDKDM4EUBE2NTSHR
SCHEMBL6848486 0.84 TNK2 (0.58) ALDH1A1HPGDKDM4EUBE2NTSHR
SCHEMBL6202986 0.83 ALDH1A1 (0.45) ALDH1A1HPGDKDM4EUBE2NTSHR
SCHEMBL1790077 0.83 ALDH1A1 (0.45) ALDH1A1HPGDKDM4EUBE2NTSHR
SCHEMBL6200264 0.79 AURKA (0.64) ALDH1A1HPGDTSHRHSD17B10MAPK1
SCHEMBL6200056 0.78 RAB9A (0.40) GSK3BRPS6KB1MAPK14CHEK1RAB9A
SCHEMBL6198489 0.77 ALDH1A1 (0.47) ALDH1A1HPGDKDM4ETSHRHSD17B10
SCHEMBL735560 0.75 TNK2 (0.68) ALDH1A1HPGDKDM4EUBE2NTSHR
SCHEMBL20492595 0.74 SMN1; SMN2 (0.43) ALDH1A1HPGDKDM4EUBE2NTSHR
SCHEMBL6198397 0.74 AURKA (0.50) ALDH1A1HPGDTSHRHSD17B10RPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1425283-B1 NOVEL 4-AMINOFUROPYRIMIDINES AND THE USE THEREOF BAYER HEALTHCARE AG (DE) 2005-03-16 EP disclosed
US-20040259888-A1 Novel 4-aminofuropyrimidines and the use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-12-23 US disclosed
EP-1425283-A1 NOVEL 4-AMINOFUROPYRIMIDINES AND THE USE THEREOF Bayer HealthCare AG (DE) 2004-06-09 EP disclosed
WO-2003018589-A1 NOVEL 4-AMINOFUROPYRIMIDINES AND THE USE THEREOF BAYER HEALTHCARE AG (DE) 2003-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259888-A1 Novel 4-aminofuropyrimidines and the use thereof DPYD, TPMT, TYMP ALDH1A1 176/4885HPGD 389/4885KDM4E 1612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.